TG Therapeutics Inc (TGTX) - Total Liabilities
Based on the latest financial reports, TG Therapeutics Inc (TGTX) has total liabilities worth $945.71 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TGTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
TG Therapeutics Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how TG Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See TG Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
TG Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of TG Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Full Truck Alliance Co Ltd ADR
NYSE:YMM
|
USA | $3.62 Billion |
|
Zhejiang Huafon Spandex Co Ltd
SHE:002064
|
China | CN¥9.37 Billion |
|
Yunnan Yuntianhua Co Ltd
SHG:600096
|
China | CN¥24.63 Billion |
|
Columbia Banking System Inc
NASDAQ:COLB
|
USA | $59.38 Billion |
|
Itissalat Al-Maghrib (IAM) S.A
F:MSPA
|
Germany | €51.67 Billion |
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
USA | $25.97 Billion |
|
Janus Henderson Group PLC
NYSE:JHG
|
USA | $2.08 Billion |
|
Western Alliance Bancorporation
NYSE:WAL
|
USA | $84.83 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down TG Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TGTX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TG Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TG Therapeutics Inc (1996–2025)
The table below shows the annual total liabilities of TG Therapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $415.23 Million | +16.86% |
| 2024-12-31 | $355.33 Million | +110.15% |
| 2023-12-31 | $169.09 Million | +25.26% |
| 2022-12-31 | $134.99 Million | -5.26% |
| 2021-12-31 | $142.48 Million | +34.04% |
| 2020-12-31 | $106.29 Million | -14.56% |
| 2019-12-31 | $124.40 Million | +108.79% |
| 2018-12-31 | $59.58 Million | -38.82% |
| 2017-12-31 | $97.38 Million | +77.76% |
| 2016-12-31 | $54.78 Million | -51.72% |
| 2015-12-31 | $113.47 Million | +30.81% |
| 2014-12-31 | $86.75 Million | +80.30% |
| 2013-12-31 | $48.11 Million | +637.50% |
| 2012-12-31 | $6.52 Million | +4.03% |
| 2011-12-31 | $6.27 Million | -73.87% |
| 2010-12-31 | $24.00 Million | +235.63% |
| 2009-12-31 | $7.15 Million | +27.12% |
| 2008-12-31 | $5.62 Million | +200.53% |
| 2007-12-31 | $1.87 Million | -3.69% |
| 2006-12-31 | $1.94 Million | +16.66% |
| 2005-12-31 | $1.67 Million | +39.32% |
| 2004-12-31 | $1.20 Million | +23.78% |
| 2003-12-31 | $966.02K | +67.21% |
| 2002-12-31 | $577.73K | +13.59% |
| 2001-12-31 | $508.61K | -75.55% |
| 2000-12-31 | $2.08 Million | +246.74% |
| 1999-12-31 | $600.00K | 0.00% |
| 1998-12-31 | $600.00K | +50.00% |
| 1997-12-31 | $400.00K | +33.33% |
| 1996-12-31 | $300.00K | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more